InsiderDB
Sign inStart free trial

Sarepta Therapeutics (SRPT)

Healthcare · Biotechnology

3 members of Congress have disclosed 7 trades in Sarepta Therapeutics (SRPT) since 2023: 3 buys and 4 sales. The most recent was disclosed on May 6, 2025.

Trades disclosed
7
Members trading
3
Buys / sells
3 / 4
Reported value
$35K–$175K

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow SRPT

What else is happening at SRPT

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. SRPTLobbying report·Lobbying disclosures

    SRPT: third_quarter 2026 lobbying report

    H.R. 9260 - LHHS Appropriations Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to Section 232

    Public: Oct 19, 2026, 4:58 PM EDTOriginal source ↗
  2. SRPTLobbying report·Lobbying disclosures

    SRPT: second_quarter 2026 lobbying report

    H.R. 9260 - LHHS Appropriations H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to supply chain Issues related to Section 232

    Public: Jul 20, 2026, 1:40 PM EDTOriginal source ↗

Who traded SRPT

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.